Hematology

Revumenib shows promise in treating NPM1-mutant AML, expanding its role in precision oncology and offering hope for targeted leukemia therapies.

Acalabrutinib shows improved safety and survival rates in chronic lymphocytic leukemia (CLL), reducing risks of mortality and cardiovascular complications.

SWIFT-seq revolutionizes multiple myeloma diagnosis, offering a noninvasive blood test that enhances monitoring and risk assessment for patients.

CPX-351 shows promise for younger adults with therapy-related AML, offering improved survival post-transplant despite lower initial remission rates.

Pharmacists play a crucial role in managing headaches in patients on complement inhibitors for PNH, ensuring proper education and risk mitigation strategies.

Birelentinib gains FDA fast track designation, offering hope for relapsed CLL/SLL patients resistant to current BTK and BCL2 therapies.

Discontinuing lenalidomide after 3 years of MRD negativity shows low relapse rates in multiple myeloma, offering hope for treatment-free remission.

Sanofi's SAR446523 receives orphan drug designation for relapsed/refractory multiple myeloma, enhancing treatment options and patient outcomes.

Pirtobrutinib shows promising results in a head-to-head trial against ibrutinib for chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL).

Luspatercept shows promise in reducing transfusion dependence for myelofibrosis-associated anemia, despite not meeting primary trial end points.

Julio C. Chavez, MD, MS, discusses the distinct pharmacologic profile, clinical activity, and outpatient potential of golcadomide plus rituximab in relapsed/refractory follicular lymphoma, highlighting its selective cereblon modulation, fixed-duration dosing, and promising efficacy in heavily pretreated patients.

Targeting BRD4 with BET inhibitors shows promise in reversing immune suppression by myeloid-derived suppressor cells in chronic lymphocytic leukemia.

Sundar Jagannath, MD, discusses how prophylactic tocilizumab reduced cytokine release syndrome incidence and severity with talquetamab in relapsed or refractory (R/R) multiple myeloma.

Andrew H. Wei, PhD, discusses phase 1b findings on the safety, pharmacokinetics, and preliminary efficacy of combining the menin inhibitor bleximenib with venetoclax and azacitidine in patients with newly diagnosed or relapsed/refractory acute myeloid leukemia (AML) harboring NPM1 mutations or KMT2A rearrangements.

The advisory committee cited concerns around ocular toxicity and overall tolerability, raising serious questions about the drug's benefit-risk profile ahead of its scheduled Prescription Drug User Fee Act action date on July 23, 2025.

The CRL states that the STARGLO data do not provide sufficient evidence to support the second-line indication in the US patient population.

ImCheck's ICT01 gains an orphan drug designation from the FDA, offering hope for acute myeloid leukemia (AML) treatment in older patients with limited options.

The updated version 1.2026 NCCN Guidelines for chronic myeloid leukemia (CML) emphasize individualized treatment strategies, TKI-specific considerations, drug interaction management, and pregnancy safety, highlighting the critical role of oncology pharmacists in optimizing therapy selection, patient counseling, and cost-effective care.

An adjusted analysis of the ALPINE and ASCEND trials revealed a statistically significant progression-free survival advantage for zanubrutinib.

The data highlight novel therapies and biomarkers shaping personalized cancer care.

The data showed patients with relapsed or refractory multiple myeloma achieved a 73% overall response rate.

The long-term outcomes from the CARTITUDE-1 trial in multiple myeloma and durable complete response data from the STARGLO trial in diffuse large B-cell lymphoma can be significant for these disease states.

New research highlights the lower infection risk with zanubrutinib compared with venetoclax in CLL/SLL treatment, offering safer options for patients.

New data reveal isatuximab-based therapy achieves high MRD-negativity rates in newly diagnosed multiple myeloma.

CARTITUDE-1 trial reveals cilta-cel's potential in achieving long-term remission for relapsed/refractory multiple myeloma, sparking discussions on curative possibilities.